Andrew X. Zhu, MD, PhD

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA

Dr. Andrew X. Zhu is Professor of Medicine at Harvard Medical School and Director of Liver Cancer Researchat Massachusetts General Hospital Cancer Center.  The major focus of his research is to develop more effective therapies forhepatocellular carcinoma (HCC) and cholangiocarcinomathrough phase I, II and III clinical trials.  The second area of his research interests is directed at the development of novel circulating and imaging biomarkers for targeted therapeutics that have prognostic and/or predictive significance.  The third area of his research is to define and characterize known or novel genetic mutations in HCC and cholangiocarcinoma and assess their potential correlation with clinical outcomes and as therapeutic targets.

As a widely published author, Dr. Zhu has served as a principle investigator in many clinical trials in HCC, cholangiocarcinoma and other gastrointestinal cancers.  He is the invited reviewer for many medical journals and has lectured extensively on HCC and other gastrointestinal cancers.  An internationally recognized leader in HCC and cholangiocarcinoma, he has led early efforts of developing several molecularly targeted agents in liver cancers and studying the predictive and surrogate circulating and imaging biomarkers.  He is a founding board member of the International Liver Cancer Association, Fellow of American College of Physicians, and a member of the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research.  Dr. Zhu serves on the Hepatobiliary Cancer committee of the National Comprehensive Cancer Network, the Grants Selection Committee of ASCO, and the Hepatobiliary Cancer Task Force of The NCI Gastrointestinal Cancer Steering Committee (GISC).  He has received several awards for his work, including V Foundation Translational Research Award, Lorenzo Cappussotti Award, and Jonathan Kraft Translational Award.